Navigation Links
PEAK Surgical Announces Completion of First PRECISE Clinical Study, Receipt of Medical Design Excellence Award for PEAK(R) Surgery System and Achievement of Over 1,000 Surgeries Using PEAK PlasmaBlade(TM)
Date:4/7/2009

/b>

For decades, surgeons have relied on scalpels to cut skin and delicate tissues and have used electrosurgical devices to cut and coagulate fat and other thicker, tougher tissues. Although scalpels precisely cut tissue, they do not control bleeding. Electrosurgical devices, on the other hand, cut efficiently and control bleeding but cause extensive thermal damage to surrounding tissue. In cases where the risk of collateral damage or scarring from electrosurgery is considered to be unacceptable, surgeons must use both a traditional scalpel for cutting and an electrosurgical device for coagulation.

The PlasmaBlade family of devices offers the precision of a scalpel and the bleeding control of a traditional electrosurgery device in a single surgical instrument. The PlasmaBlade family includes the PlasmaBlade 4.0, which is designed to be used to cut through all types of soft tissue, including skin, fat and muscle; the PlasmaBlade Needle, which has a fine needlepoint tip and is specifically designed for ultra-precise surgical procedures; and the PlasmaBlade EXT, which is designed for use in surgical procedures requiring an extended-reach tip.

Unlike most radiofrequency-based surgical products that use continuous voltage waveforms to cut tissue, the PULSAR Generator supplies pulsed plasma radiofrequency energy to the PlasmaBlade to incise tissue and control bleeding. Because the radiofrequency energy is provided through short on-and-off pulses via a highly insulated cutting electrode, the PlasmaBlade cuts at half the average temperature of a conventional electrosurgery device and can be as low as 50 degrees Centigrade. This temperature reduction results in significantly less damage to surrounding tissues compared to traditional electrosurgery. The PlasmaBlade is also able to dissect tissue in a completely submerged surgical field, another shortcoming of traditional electrosurgical devices.

Preclinical results ha
'/>"/>

SOURCE PEAK Surgical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Innocoll Announces Dosing of Last Patient in Second US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Colorectal Surgery Patients
2. Innocoll Announces Dosing of Last Patient in US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Cardiac Surgery Patients
3. Children and Orthopaedic Surgical Emergencies
4. Novel Product for Post Surgical Scar Formation Entering Clinical Development
5. ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
6. PEAK Surgical Receives 510(k) Clearance to Market PEAK(R) Surgery System for Use in Expanded Indications
7. News Media Advisory: Worlds Leading Surgical Oncologists to Gather at McLaren Regional Medical Center to Present Latest Work on Breast, Gastrointestinal Cancer Treatments
8. American Heart Association Journal Report: Surgical Residents Perform Heart Surgery as Effectively as Staff Surgeons
9. PEAK Surgical Announces Positive Results From Preclinical Study of PEAK PlasmaBlade(TM) Needle
10. Morse CyberKnife CEO James G. Schwade, M.D. Announces Non-Surgical Treatment With CyberKnife Radiosurgery for Prostate Cancer
11. Innocoll Announces Dosing of Last Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-Operative Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... 2014 Research and Markets has ... by Equipment, by Reagent, by Application - Global Forecast ... http://photos.prnewswire.com/prnh/20130307/600769 Biopharmaceuticals are ... one of the most important and widely used techniques ... segment of the cell culture market in 2013. Growth ...
(Date:7/22/2014)... 22, 2014  Decision Resources Group finds that the market ... will remain relatively stagnant at a value of around ... percutaneous coronary intervention (PCI) volumes are growing faster in ... as the United States and ... by the increase in penetration of PCI procedures relative to ...
(Date:7/22/2014)... , July 22, 2014 Legislation backed ... Access to Local Pharmacies Act of 2014") championing ... D would undermine the availability of lower cost ... $21 billion over the next 10 years, according ... by the Pharmaceutical Care Management Association (PCMA). ...
Breaking Medicine Technology:Global Cell Culture (Bioreactor, Incubator, Centrifuge) Market - Forecast to 2018 2Global Cell Culture (Bioreactor, Incubator, Centrifuge) Market - Forecast to 2018 3The Canadian Interventional Cardiology Device Market Will Remain Relatively Stagnant Through 2022 at Around $80 Million 2The Canadian Interventional Cardiology Device Market Will Remain Relatively Stagnant Through 2022 at Around $80 Million 3New Study: H.R. 4577 to Cost $21 Billion over 10 Years 2New Study: H.R. 4577 to Cost $21 Billion over 10 Years 3
... Mylan Inc. (Nasdaq: MYL ) today ... final approval from the U.S. Food and Drug Administration ... Valacyclovir Hydrochloride Tablets, 500 mg (base) and 1000 mg ... for the herpes virus infection. The product is being ...
... National Anesthesia Services, Inc. celebrates its 21st anniversary as one of ... a locum tenens and permanent basis in hospitals, surgery centers and medical ... , , ... when we first began," said president and owner Stephen Read . ...
Cached Medicine Technology:Mylan Receives Approval for Generic Version of Valtrex® 2National Anesthesia Services, Inc. Celebrates 21 Years of Dynamic Growth and Achievement 2
(Date:7/22/2014)... on cholesterol treatment and cardiovascular risk assessment state that ... from atherosclerotic cardiovascular disease or of having a heart ... risk profile (based on age, smoking history, and cholesterol ... for when and how aggressively to treat high cholesterol ... Men,s Health , a peer-reviewed publication from Mary Ann ...
(Date:7/22/2014)... (LALCA 2014) will be held August 21 23, ... the leading cause of death not only in Latin ... previous conferences in Chile, Mexico, Argentina and Brazil, international ... in the treatment and prevention of lung cancer and ... With tobacco being the leading cause of morbi-mortality worldwide ...
(Date:7/22/2014)... The Beryl Institute announces its fifth annual ... Program. These offerings reinforce the Institute’s commitment to support ... and the need for rigorous research to understand and ... programs are intended to encourage and support research ... on the patient experience before, during and after care ...
(Date:7/22/2014)... Ticket Down is a reliable source for cheap Manchester ... MD. There has never been a better time in the ... success of the American national soccer team at the 2014 World ... that fans of the world’s sport will be able to feed ... Champions Cup. The tournament will kick off on July 24 and ...
(Date:7/22/2014)... New York, NY (PRWEB) July 22, 2014 ... Risperdal lawsuits ( http://www.risperdallawsuitcenter.com/ ) in ... his decision to deny punitive damages in cases ... (male breast growth), Bernstein Liebhard LLP reports. In ... New also denied a plaintiffs’ request to certify ...
Breaking Medicine News(10 mins):Health News:The Beryl Institute Opens Applications for 2014 Patient Experience Grant and Scholar Programs 2Health News:The Beryl Institute Opens Applications for 2014 Patient Experience Grant and Scholar Programs 3Health News:Manchester United vs. Inter Milan Tickets Fedex Field Landover: Ticket Down Slashes Ticket Prices for Inter Milan ManU International Champions Cup Match in Washington, DC 2Health News:Manchester United vs. Inter Milan Tickets Fedex Field Landover: Ticket Down Slashes Ticket Prices for Inter Milan ManU International Champions Cup Match in Washington, DC 3Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 4
... taking the contraceptive pill may find themselves less responsive to ... The study, published in the journal Human Reproduction, measured the ... - while taking and not taking the Pill. ... experienced rises and falls in their ability to sense smells, ...
... vocal cords improves voice problems in Parkinson's disease. One of ... voice quality experienced by some patients. This problem is known ... abnormalities in the area of the voice box or larynx.// ... may be hard to understand what they are saying. You ...
... might explain common digestive symptoms like gas, pain and ... the link between fructose intolerance and the symptoms of ... abdominal discomfort, bloating and changes in bowel habit. Fructose ... honey. Some people can't digest it, but the condition ...
... past evidence that hormone replacement might lower stroke risk ... does not protect women from recurrent strokes and may ... evidence that hormone replacement therapy does not have the ... doctors have long thought hormone replacement therapy might help ...
... cheese and whole milk may be at increased risk ... The rates of two types of cancer--gastric cardia and ... 30 years. To investigate potential links between these and ... dietary factors, Dr. Susan T. Mayne from Yale University ...
... who undergo surgery for breast cancer will experience ... surgery, according to new research. Dr. Erica S. ... colleagues reported the findings at the American Public ... researchers asked 266 women who had undergone breast ...
Cached Medicine News:
... Mammography has been FDA approved, and represents ... It is the first and only mammography ... - the highest available. SenoScan's larger field ... breast support is more comfortable and helps ...
... The P3000 heralds a new concept in pupillometry, ... infrared optical system developed for the P2000. ... in which we have paid particular attention to ... Our new system is extremely flexible, allowing you ...
... the most useful features is the PupilFit ... mathematical analysis of the pupil images, producing ... instantaneously. The fitted circle is shown as ... proof that the measurement ismeaningful, and not ...
... An easy-to-operate, semi-automatic urine analyzer that ensures ... your lab efficiency by reducing "hands on" ... makes it an ideal fit for work ... Criterion II Analyzer is designed for continuous ...
Medicine Products: